(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says auditor request additional time to complete standard audit of its results of financial year 2023 that ended on April 30. Cites unforeseen circumstances impacting the audit engagement team. Says audit is substantially complete without any material audit issues. Read More
Oxford Technology 2 VCT PLC - venture capital trust investing in quoted and unquoted technology companies - Net asset value of OT1 shares falls by 16% to 37.9 pence on August 31 from 45.3p on February 28. Similarly, NAV of OT2 shares falls to 20.5p from 25.1p, of OT3 shares to 23.6p from 33.7p, and of OT4 shares to 25.4p from 29.7p. No dividends are paid during the half year, nor are any shares bought back. Read More
(Alliance News) - Scancell Holdings PLC shares surged on Tuesday after the company announced positive results from the phase 2 clinical trial of its SCIB1 treatment for advanced melanoma. Read More
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Hires Sath Nirmalananthan to be chief financial officer, starting immediately. Nirmalananthan previously was CFO for Europe, Middle East & Africa at Prenetics Ltd, a genomics-driven health sciences company. His appointment at Scancell follows Keith Green's retirement as director of finance. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Scancell Holdings PLC on Monday said it has expanded its Modi-1 trial for the use of checkpoint inhibitors on cancer patients. Read More
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Will focus on lead cancer vaccine assets SCIB1 and Modi-1 following encouraging data from clinical trials. Adds phase two single arm scope trial investigating the safety and tolerability of using SCIB1 in combination with checkpoint inhibitors in patients with advanced melanoma is progressing well and notes a potential pathway for a registration trial. Adds it is fully funded to the second half of 2024 due to its increasing focus on the two clinical assets. Read More
(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Scancell Holdings PLC on Tuesday said that it has completed the monotherapy dose finding arm of its multicentre Phase 1/2 ModiFY clinical trial, designed to treat cancer patients. Read More
(Alliance News) - Scancell Holdings PLC on Monday reported a positive response in its 'Covidity' trial, which aims to deliver needle-free injectable Covid vaccines. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Scancell Holdings PLC on Monday said it has in-licensed SNAPvax technology from Vaccitech PLC to help develop its cancer treatments. Read More
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to GBP3.8 million from GBP16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of GBP7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year. Read More
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair. Read More
(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More